阿帕替尼治疗晚期胃癌的临床疗效观察

Clinic observation of apatinib in treatment of advancedgastric carcinoma

目的:探讨阿帕替尼治疗晚期胃癌患者的临床疗效和安全性。方法:回顾性分析我院2016年1月至2017年2月接受阿帕替尼治疗的28例化疗失败的胃癌患者,给予阿帕替尼500 mg/d,直至患者出现疾病进展或不可耐受的不良反应,分析其疗效和安全性。结果:阿帕替尼治疗晚期胃癌的有效率(RR)为10.7%,疾病控制率(DCR)为42.8%,中位无进展生存时间(PFS)为3.6个月,中位总生存时间(OS)为5个月,患者耐受性良好,常见的不良反应为高血压、手足综合征和蛋白尿。结论:阿帕替尼治疗二线或以上化疗失败的晚期胃癌具有良好的疗效和安全性。

Objective：To evaluate the efficacy and toxicity of apatinib mesylate in treatment of advanced gastric carcinoma.Mathods：Twenty-eight patients with treatment of advanced gastric carcinoma were recruited from Janurary 2016 to February 2017.All patients were received apatinib mesylate 500 mg/d orally until disease progression or intolerable toxicity.Clinical efficacy and adverse reactions were observed.Results：The total response rate and disease control rate was 10.7% and 42.8%.Median local progression-free survival and median overall survival was 3.6 months and 5 months.Apatinib mesylate was well tolerated without severe toxicities.The main adverse reactions were hypertension,hand-footsyndrome,proteinuria,mostly degree Ⅰor Ⅱ.Conclusion：Apatinib mesylate is effective and tolerable for advanced gastric carcinoma patients that failed second-line or above chemotherapy.